文献速递血栓与止血

他汀类药物使用与急性症状性肺栓塞患者30天死亡率

Statin use and 30-day mortality in patients with acute symptomatic pulmonary embolism.
PubMed 文献 · J Thromb Haemost · 2022-05-22

基于注册研究31 169例急性肺栓塞患者,5520例(18%)基线使用他汀,其中低强度829例、中等强度3636例、高强度1055例。多变量分析显示他汀使用者30天全因死亡风险低于非使用者(OR 0.65,95%CI 0.56-0.76),致死性肺栓塞风险亦较低(OR 0.42,95%CI 0.28-0.62)。作者认为需随机试验确认这些数据。

要点

  • 急性肺栓塞患者中基线他汀使用与30天全因死亡风险降低相关(OR 0.65,95%CI 0.56-0.76)。
  • 他汀使用与致死性肺栓塞风险降低相关(OR 0.42,95%CI 0.28-0.62)。
  • 低、中、高强度他汀均与死亡风险降低相关,且他汀与癌症死亡率无显著关联。

核心结论

  • 基线使用他汀的肺栓塞患者30天内死亡风险显著低于非使用者,作者认为需随机试验确认这些数据。

研究设计与样本

  • 基于Registro Informatizado de Pacientes con Enfermedad TromboEmbólica注册研究数据,比较急性肺栓塞患者中他汀使用者与非使用者的30天全因死亡率,次要结局为致死性肺栓塞,并以癌症相关死亡率作为证伪终点。
  • 2009年1月至2021年4月共纳入31 169例肺栓塞患者,其中5520例(18%)基线使用他汀:低强度829例、中等强度3636例、高强度1055例。

主要发现

  • 他汀使用者较非使用者年龄更大,糖尿病、高血压或动脉粥样硬化性疾病的发生率更高(所有比较P<0.001)。
  • 前30天内共有1475例患者死亡,其中致死性肺栓塞255例。
  • 多变量分析显示,他汀使用者全因死亡风险低于非使用者(OR 0.65,95%CI 0.56-0.76),致死性肺栓塞风险亦低于非使用者(OR 0.42,95%CI 0.28-0.62)。
  • 低强度他汀使用者死亡风险OR 0.51(95%CI 0.34-0.77)、中等强度OR 0.68(95%CI 0.57-0.81)、高强度OR 0.68(95%CI 0.51-0.92),均低于非使用者。
  • 以医院为随机效应的混合效应logistic回归模型结果不变;他汀与癌症死亡率(证伪终点)无显著关联。

临床怎么用

  • 原文结论未据此给出临床推荐,仅指出需随机试验确认这些数据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Statins possess antithrombotic and profibrinolytic properties. The association between statin use and short-term outcomes in patients with acute pulmonary embolism (PE) remains unknown. METHODS: We used the data from the Registro Informatizado de Pacientes con Enfermedad TromboEmbólica registry to compare the 30-day all-cause mortality in patients with acute PE according to the use of statins. Secondary outcome was fatal PE. We used cancer-related mortality as a falsification endpoint. RESULTS: From January 2009 to April 2021, 31 169 patients with PE were recruited. Of these, 5520 (18%) were using statins at baseline: low intensity: 829, moderate: 3636, high intensity: 1055. Statin users were older and had a higher frequency of diabetes, hypertension, or atherosclerotic disease than non-users (P <0.001 for all comparisons). During the first 30 days, 1475 patients died (fatal PE, 255). On multivariable analysis, statin users had a lower risk of all-cause death (odds ratio [OR]: 0.65; 95% confidence interval [CI]: 0.56-0.76) and fatal PE (OR: 0.42; 95% CI: 0.28-0.62) than non-users. The risk for death was lower in patients using either low- (OR: 0.51; 95% CI: 0.34-0.77), moderate- (OR: 0.68; 95% CI: 0.57-0.81), or high-intensity statins (OR: 0.68; 95% CI: 0.51-0.92). Results did not change in mixed effects logistic regression models with hospitals as a random effect. Statins were not associated with a significant chance in cancer mortality (falsification endpoint). CONCLUSIONS: PE patients using statins at baseline had a significantly lower risk of dying within the first 30 days than non-users. Randomized trials are needed to confirm these data.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Siniscalchi C, Muriel A, Suriñach Caralt JM, et al. Statin use and 30-day mortality in patients with acute symptomatic pulmonary embolism. J Thromb Haemost. 2022. PMID: 35510755. doi:10.1111/jth.15753

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。